Amgen Inc. $AMGN Shares Sold by Matrix Asset Advisors Inc. NY

Matrix Asset Advisors Inc. NY lessened its position in shares of Amgen Inc. (NASDAQ:AMGN) by 2.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 103,549 shares of the medical research company’s stock after selling 2,682 shares during the quarter. Amgen comprises 3.0% of Matrix Asset Advisors Inc. NY’s investment portfolio, making the stock its 11th biggest holding. Matrix Asset Advisors Inc. NY’s holdings in Amgen were worth $33,892,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the company. Board of the Pension Protection Fund acquired a new stake in shares of Amgen in the fourth quarter valued at approximately $26,000. Howard Hughes Medical Institute acquired a new position in shares of Amgen in the 2nd quarter valued at $32,000. Olistico Wealth LLC acquired a new position in shares of Amgen in the 4th quarter valued at $33,000. Cloud Capital Management LLC purchased a new stake in Amgen in the 3rd quarter valued at $34,000. Finally, Saranac Partners Ltd acquired a new stake in Amgen during the 3rd quarter worth $37,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of AMGN opened at $353.28 on Thursday. The stock has a market capitalization of $190.44 billion, a P/E ratio of 24.83, a P/E/G ratio of 3.49 and a beta of 0.47. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $391.29. The company’s fifty day moving average is $363.57 and its two-hundred day moving average is $331.74.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same quarter last year, the business earned $5.31 EPS. The business’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, sell-side analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s payout ratio is currently 70.84%.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Analyst/sector endorsements: recent analyst commentary (Zacks) highlights Amgen’s strong drug portfolio and resilience versus sector headwinds, which supports investor sentiment and helps the stock. The Zacks Analyst Blog Roche Holding, AT&T and Amgen
• Positive Sentiment: Inclusion in buy lists: Amgen appears in a recent “5 Best Pharma Stocks to Invest In Now” roundup, which can attract longer?term inflows and positive sentiment from retail/institutional investors. 5 Best Pharma Stocks to Invest In Now
• Neutral Sentiment: Brokerage consensus: a recent survey shows AMGN carries an average “Hold” rating from brokerages — not a downgrade but a sign analysts see limited near?term upside absent new catalysts. Amgen Inc. (NASDAQ:AMGN) Given Average Rating of “Hold” by Brokerages
• Negative Sentiment: Safety alert on Tavneos: the U.S. FDA has flagged multiple cases of drug?induced liver injury — including deaths — linked to Amgen’s rare?disease drug Tavneos (76 cases identified). The agency is urging closer monitoring and prompt discontinuation if liver damage is suspected; this poses regulatory, reputational and potential liability risks that could pressure the stock. US FDA warns of liver injury cases tied to Amgen’s rare disease drug FDA Says Amgen’s Tavneos Linked to Liver Injuries, Deaths
• Negative Sentiment: Biosimilars competition: Teva won FDA approval for a Prolia biosimilar (Ponlimsi) and advanced other biosimilar filings — increased biosimilars activity raises competitive pressure in areas where Amgen has legacy biologics, potentially weighing on future sales. TEVA’s Prolia Biosimilar Gets FDA Nod, Xolair Filing Accepted

Wall Street Analyst Weigh In

AMGN has been the topic of several research reports. TD Cowen reissued a “buy” rating on shares of Amgen in a research report on Wednesday, February 4th. Jefferies Financial Group started coverage on shares of Amgen in a report on Tuesday, March 10th. They issued a “hold” rating and a $350.00 target price for the company. Oppenheimer set a $400.00 price target on Amgen and gave the stock an “outperform” rating in a report on Thursday, January 29th. Wells Fargo & Company boosted their price target on Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a research report on Thursday, March 19th. Finally, Truist Financial upped their price objective on Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a research note on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Amgen presently has a consensus rating of “Hold” and a consensus price target of $354.60.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.